About the Company
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ALGS News
Aligos Therapeutics Inc (ALGS)
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue Estimates
Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.89 per share a year ago. These ...
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver and viral diseases.
SVB Securities Sticks to Its Hold Rating for Aligos Therapeutics (ALGS)
See which 3 stocks are most likely to make moves following their insider activities. Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing ...
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue Estimates
Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.89 per share a year ago.
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarterand Full Year 2022 ...
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver and viral diseases.
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to ...
Loading the latest forecasts...